Developing new blood tests to identify treatment-resistant prostate cancer
The next generation of liquid biopsies: Predictive and pharmacologic biomarkers
This study is looking at new blood tests to find specific signs of prostate cancer that doesn't respond to treatment, helping doctors create more personalized and effective treatment plans for patients with advanced prostate cancer.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Wisconsin-Madison NIH-funded |
| Lab location | 1 site (Madison, United States) |
| Project ID | NIH-10977893 on NIH RePORTER |
What this research studies
This research focuses on creating innovative blood tests, known as liquid biopsies, to identify specific biomarkers that indicate treatment-resistant prostate cancer. By analyzing genetic and epigenetic changes in cancer cells found in the bloodstream, the researchers aim to uncover new vulnerabilities in the cancer that can be targeted with precision therapies. The findings will be translated into clinical trials to improve treatment strategies for patients with advanced prostate cancer. This approach could lead to more personalized treatment options based on individual tumor characteristics.
Who could benefit from this research
Good fit: Ideal candidates for this research are men diagnosed with advanced prostate cancer, particularly those who have shown resistance to current androgen receptor-targeted therapies.
Not a fit: Patients with early-stage prostate cancer or those who have not undergone treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients with advanced prostate cancer who have not responded to standard therapies.
How similar studies have performed: Previous research has shown promise in using liquid biopsies for cancer detection and monitoring, indicating that this approach has the potential for success.
Where this research is happening
Madison, United States
- University of Wisconsin-Madison — Madison, United States (Active)
Researchers
- Principal investigator: Sperger, Jamie M — University of Wisconsin-Madison
- Study coordinator: Sperger, Jamie M
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.